Developing selectively nonselective drugs for treating CNS disorders

John Gray, Bryan L. Roth

Research output: Contribution to journalArticlepeer-review

7 Scopus citations


For the past two decades, drug discovery has been dominated by the 'magic bullet' or single molecular target-based approach. But for many diseases of the central nervous system, especially complex polygenic disorders such as schizophrenia, the most effective drugs have affinity for many molecular targets. Various methods have been recently proposed for developing so-called 'selectively nonselective drugs' or 'magic shotguns' - that is, therapeutics with more complex pharmacological profiles.

Original languageEnglish (US)
Pages (from-to)413-419
Number of pages7
JournalDrug Discovery Today: Therapeutic Strategies
Issue number4
StatePublished - Jun 2006
Externally publishedYes

ASJC Scopus subject areas

  • Drug Discovery
  • Molecular Medicine


Dive into the research topics of 'Developing selectively nonselective drugs for treating CNS disorders'. Together they form a unique fingerprint.

Cite this